UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 9, 2009
ACADIA PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in Charter)
| DELAWARE | 000-50768 | 06-1376651 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| 3911 SORRENTO VALLEY BOULEVARD SAN DIEGO, CALIFORNIA |
92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(858) 558-2871
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02. | Results of Operations and Financial Condition. |
On November 9, 2009, ACADIA Pharmaceuticals Inc. issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2009. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | The following exhibit is furnished herewith: |
| 99.1 | Press release dated November 9, 2009 |
2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ACADIA Pharmaceuticals Inc. | ||||||
| Date: November 9, 2009 | By: | /s/ THOMAS H. AASEN | ||||
| Thomas H. Aasen | ||||||
| Vice President, Chief Financial Officer, Treasurer, and Secretary | ||||||
3.
INDEX TO EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Press release dated November 9, 2009 |
4.
Exhibit 99.1
Contacts:
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871
ACADIA PHARMACEUTICALS REPORTS
THIRD QUARTER 2009 FINANCIAL RESULTS
SAN DIEGO, CA November 9, 2009 – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2009.
ACADIA reported a net loss of $8.7 million, or $0.23 per common share, for the third quarter of 2009 compared to a net loss of $15.6 million, or $0.42 per common share, for the third quarter of 2008. For the nine months ended September 30, 2009, ACADIA reported a net loss of $36.5 million, or $0.98 per common share, compared to a net loss of $50.3 million, or $1.36 per common share, for the comparable period of 2008.
At September 30, 2009, ACADIA’s cash, cash equivalents, and investment securities totaled $54.9 million compared to $60.1 million at December 31, 2008.
“The cost saving measures that we recently have undertaken extended our cash runway through 2011 and have positioned ACADIA to continue to pursue its portfolio of product candidates that provide multiple clinical and commercial opportunities,” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. “While we were disappointed with the results of the first Phase III trial in Parkinson’s disease psychosis announced during the third quarter, we remain enthusiastic about the broad development strategy we are pursuing together with Biovail, which provides the opportunity to fully explore the clinical and commercial potential of pimavanserin over three different neurological and psychiatric indications with large unmet medical needs.”
Revenues increased to $2.4 million for the third quarter of 2009 from $282,000 for the third quarter of 2008. This increase was primarily due to $1.9 million in revenues recognized under ACADIA’s collaboration with Biovail, which commenced in May 2009, as well as increased revenues from other agreements.
Research and development expenses decreased to $9.2 million for the third quarter of 2009, including $280,000 in stock-based compensation, from $13.4 million for the third quarter of 2008, including $346,000 in stock-based compensation. The decrease in research and development expenses was primarily due to $3.6 million in decreased personnel and other costs associated with ACADIA’s research and development organization following a restructuring in August 2008, and lower external service costs. External service costs totaled $6.1 million for the third quarter of 2009, compared to $6.6 million for the third quarter of 2008, and were primarily comprised of development costs for pimavanserin.
General and administrative expenses decreased to $2.0 million for the third quarter of 2009, including $331,000 in stock-based compensation, from $3.0 million for the third quarter of 2008, including $446,000 in stock-based compensation. The decrease in general and administrative expenses was primarily due to $813,000 in decreased personnel costs, and lower external service costs.
In October 2009, ACADIA implemented a restructuring to further streamline its operations, reduce its internal operating expenses, and extend its cash runway. Following these cost saving measures, ACADIA currently anticipates that its cash, cash equivalents and investment securities will be in the range of $43 to $45 million at December 31, 2009, and that the Company’s existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations through the end of 2011.
Conference Call and Webcast Information
ACADIA management will review its third quarter results and development programs via conference call and webcast today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-510-0707 for participants in the U.S. or Canada and 617-597-5376 for
international callers (reference passcode 92783090). A telephone replay of the conference call may be accessed through November 23, 2009 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 21130876). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there until November 23, 2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA’s product candidates include pimavanserin in Phase III development for Parkinson’s disease psychosis in collaboration with Biovail, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and AM-831 in IND-track development in collaboration with Meiji Seika Kaisha. All of the product candidates in ACADIA’s pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs either alone or with a partner, including clinical trials and the results therefrom, and the benefits to be derived from ACADIA’s product candidates, in each case including pimavanserin, potential payments under its collaboration agreements, its future cash position and the length of its cash runway. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, and collaborations with others, and the fact that past results of clinical trials may not be indicative of further trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2008 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2009 | 2008 | 2009 | 2008 | |||||||||||||
| Collaborative revenues |
$ | 2,435 | $ | 282 | $ | 4,630 | $ | 1,265 | ||||||||
| Operating expenses |
||||||||||||||||
| Research and development (includes stock-based compensation of $280, $346, $784 and $1,141, respectively) |
9,215 | 13,397 | 33,749 | 44,604 | ||||||||||||
| General and administrative (includes stock-based compensation of $331, $446, $1,018 and $1,298, respectively) |
1,994 | 2,974 | 7,643 | 9,428 | ||||||||||||
| Total operating expenses |
11,209 | 16,371 | 41,392 | 54,032 | ||||||||||||
| Loss from operations |
(8,774 | ) | (16,089 | ) | (36,762 | ) | (52,767 | ) | ||||||||
| Interest income (expense), net |
46 | 475 | 306 | 2,486 | ||||||||||||
| Net loss |
$ | (8,728 | ) | $ | (15,614 | ) | $ | (36,456 | ) | $ | (50,281 | ) | ||||
| Net loss per common share, basic and diluted |
$ | (0.23 | ) | $ | (0.42 | ) | $ | (0.98 | ) | $ | (1.36 | ) | ||||
| Weighted average common shares outstanding, basic and diluted |
37,383 | 37,137 | 37,262 | 37,098 | ||||||||||||
ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(Unaudited)
| September 30, 2009 |
December 31, 2008(1) | |||||
| Assets |
||||||
| Cash, cash equivalents, and investment securities |
$ | 54,909 | $ | 60,083 | ||
| Prepaid expenses, receivables and other current assets |
1,895 | 2,299 | ||||
| Total current assets |
56,804 | 62,382 | ||||
| Property and equipment, net |
1,498 | 2,103 | ||||
| Other assets |
173 | 192 | ||||
| Total assets |
$ | 58,475 | $ | 64,677 | ||
| Liabilities and Stockholders’ Equity |
||||||
| Current liabilities |
15,248 | 11,051 | ||||
| Long-term liabilities |
24,260 | 634 | ||||
| Stockholders’ equity |
18,967 | 52,992 | ||||
| Total liabilities and stockholders’ equity |
$ | 58,475 | $ | 64,677 | ||
| (1) | The condensed consolidated balance sheet at December 31, 2008 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. |